1. Pink Sheet
  2. >>Geography
  3. >>North America

FDA Needs More Time To Review Sugammadex Inspection Report, Cancels Advisory Committee

 
• By Derrick Gingery

Merck’s anesthesia reversal agent, which was deemed “not approvable” in 2008, faces another setback as FDA cancels its July 18 advisory committee meeting to allow more time to review clinical trial site inspection data.

It appears a last-minute data issue may have complicated the review of Merck & Co. Inc.’s anesthesia injection sugammadex.

FDA announced July 16, two days before a scheduled Anesthetic and Analgesic Drug Products Advisory Committee meeting to consider the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America